BIO vs. BMY: Bio-Rad Laboratories vs. Bristol-Myers Squibb Stock Comparison

Company Profile

Bio-Rad Laboratories (BIO) and Bristol-Myers Squibb (BMY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO is classified in Life Sciences Tools & Services while BMY is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Bristol-Myers Squibb (BMY) is heavily traded at around 10.85M shares per day, whereas Bio-Rad Laboratories (BIO) sees a more moderate 250.78K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Bio-Rad Laboratories (BIO) at 14.27% and Bristol-Myers Squibb (BMY) at 44.01% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Bio-Rad Laboratories (BIO) at 39.45% and Bristol-Myers Squibb (BMY) at 18.47% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Bristol-Myers Squibb (BMY) at 33.79% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Bio-Rad Laboratories (BIO) at 0.65% and Bristol-Myers Squibb (BMY) at -0.22% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Neither Bio-Rad Laboratories (BIO) nor Bristol-Myers Squibb (BMY) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while Bristol-Myers Squibb (BMY) at 1.59 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BMY.

Bio-Rad Laboratories (BIO) at 0.18 is near its industry mid-range for debt-to-equity ratio, while Bristol-Myers Squibb (BMY) at 1.91 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Bio-Rad Laboratories (BIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a yield of 3.99%, ranking against industry peers normally.

Bio-Rad Laboratories (BIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a payout of 55.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while Bristol-Myers Squibb (BMY) at 13.78 is closer to its industry’s usual earnings multiple — a discount for BIO, though growth and earnings durability still matter.

Bristol-Myers Squibb (BMY) at 2.54 sits in the cheaper P/S ratio quartile while Bio-Rad Laboratories (BIO) at 3.96 prices around its industry’s middle — BMY costs less per dollar of sales, though read it alongside growth and margins.

Bio-Rad Laboratories (BIO) at 1.35 sits in the lower P/B ratio quartile against book while Bristol-Myers Squibb (BMY) at 5.43 is valued near its industry’s middle — BIO is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics